Moderna Raises FY26 Sales Growth Guidance To 15%-25% From 10%; On Track To Achieve FY26 Gross Margin Expansion Of ~10 Percentage Points Excluding Litigation Settlement Charge; Expects Annual Cash Costs Of ~$4B-$4.5B Over 2027-2030; Sees Ending 2026 With...

Benzinga
在Benzinga上打开